Loading organizations...
Based in Mountain View, California, Digbi Health is a digital therapeutics company utilizing genetics, gut microbiome analysis, and artificial intelligence to deliver personalized treatment programs for chronic illnesses. Operating on a B2B2C model, the firm provides its services as fully covered health benefits to members of seven health plans and over one hundred employer networks. Through these enterprise partnerships, the platform is accessible to 35 million users seeking care for obesity, cardiometabolic conditions, skin diseases, and inflammatory digestive disorders. Founded in 2019 by Ranjan Sinha, the organization has raised $8.5 million in total funding, including a $5.4 million Series A round backed by Accel, Ocean Azul Partners, and Seraph Venture. Prior to launching its 2024 equity crowdfunding campaign on StartEngine, the profitable company achieved a two hundred percent growth rate in new members and employer customers.
Digbi Health has raised $5.4M across 1 funding round.
Digbi Health has raised $5.4M in total across 1 funding round.
Digbi Health has raised $5.4M across 1 funding round. Most recently, it raised $5.4M Series A in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 18, 2021 | $5.4M Series A | Radhika Ananth | Ocean Azul Partners, Seraph Group | Announced |
Digbi Health has raised $5.4M in total across 1 funding round.
Digbi Health's investors include Radhika Ananth, Ocean Azul Partners, Seraph Group.
Digbi Health is a digital therapeutics company that builds a personalized care platform using AI, genetics, and gut microbiome analysis to treat chronic conditions like obesity, cardiometabolic diseases, digestive disorders, and mental health issues.[1][2][5] It serves employers, health plans, employees, and their families by targeting root causes through at-home testing (DNA, gut biome, glucose monitoring), food-as-medicine recommendations, health coaching, and optimized pharmaceuticals, aiming to reduce medication dependency, surgeries, and healthcare costs while making chronic illness optional.[1][3][6] The platform stratifies patients by risk, predicts care paths, and delivers 24/7 access to clinicians, nurses, nutritionists, and experts, with programs like Digbi Cares for prediabetes, T2D, PCOS, hypertension, GI issues, and obesity, and GLP-Fit™ integrating CGM for obesity treatment.[5][6][7] Growth momentum includes $5.4M funding in 2023 led by Accel, partnerships with Novo Nordisk, Collective Health, Gulf Coast Regional Blood Center, and H&R Block, plus 60+ published papers, 79 US patents, and proven outcomes like 500% improved clinical results and multi-year cost savings.[3][4][5][7][8]
Founded by Ranjan Sinha, CEO of Digbi Health, the company emerged to address limitations in one-size-fits-all digital health programs, weight loss diets, and the stigma around obesity and inflammatory comorbidities affecting 100 million Americans.[3] Sinha's vision leverages 40 years of disease research in genetics, gut biome, glucose monitoring, food-as-medicine, pharma optimization, and socio-economics, backed by a team of globally renowned gut biome scientists and doctors with 60+ publications, 79 US patents, and 10+ grants.[1][5] Early traction came from pioneering DNA and microbiome-based diagnostics for employers and payers, with pivotal moments like the 2021 Novo Nordisk Prevention Accelerator pilot for obesity prevention, 90-day H&R Block pilot rollout, and 2023 $5.4M funding from Accel, Wisdom LLP, Ocean Azul Partners, and Seraph Ventures to expand US/India teams and precision care research.[3][5][7]
Digbi Health rides the precision medicine and digital therapeutics wave, fueled by AI, genomics, and microbiome research amid rising chronic disease burdens (70% of employee healthcare costs from 400 controllable conditions).[1][3] Timing aligns with post-pandemic focus on preventive care, GLP-1 drugs like those from Novo Nordisk, and employer demands for cost-effective wellness amid obesity epidemics.[5][6] Market forces favoring it include payer/employer shifts to root-cause interventions, regulatory support for food-as-medicine, and data from wearables/CGM enabling personalization.[1][6] It influences the ecosystem by setting benchmarks for holistic obesity care (e.g., GLP-Fit™), partnering with pharma/blood centers/health platforms, and presenting breakthroughs like gut microbiome's role in endogenous GLP-1 at Obesity Society conferences, expanding access via payers/TPAs.[3][4][5][8]
Digbi Health is poised to scale through payer/employer expansions, GLP-Fit™ enhancements, and research on genetic/gut markers for inflammatory diseases, potentially capturing more of the $4T US healthcare market focused on obesity/cardiometabolics.[3][6] Trends like AI-driven personalization, microbiome therapeutics, and integrated platforms (e.g., Collective Health) will accelerate its growth, with influence evolving via pharma pilots (Novo Nordisk) and global teams strengthening clinical evidence.[5][6][8] As chronic care shifts from reactive to biology-rooted, Digbi's mission to make illness optional positions it as a leader in sustainable, equitable health transformation—echoing its founding promise to redefine care beyond one-size-fits-all failures.[1][3]
